Mar. 11, 2020 11:03 AM ET|About: Parallax Health Scienc... (PRLX)|By: Douglas W. House, SA News Editor Thinly traded nano cap Parallax Health Sciences (OTCPK:PRLX +13%) is, yet another, would-be player in the mad dash for a rapid screening test for COVID-19.
Today, it announced that subsidiary Parallax Diagnostics intends to in-license and develop monoclonal and polyclonal antibodies for such a test based on its VT-1000 immunoassay platform. Available resources appear to be an issue since it is seeking partners to accelerate the development.
Give Me A Follow If You Want To Consistently Find Winners!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.